特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
951158

癌・腫瘍プロファイリングの世界市場 (~2025年):免疫アッセイ・NGS・PCR・in-situハイブリダイゼーション・マイクロアレイ

Cancer/Tumor Profiling Market by (Technology (Immunoassay, NGS, PCR, In-Situ Hybridization, Microarray), Cancer Type (Breast, Lung, Colorectal, Prostate, Melanoma)), Biomarker Type (Genomic, Protein), Application, Region - Global Forecast to 2025

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 293 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.80円
癌・腫瘍プロファイリングの世界市場 (~2025年):免疫アッセイ・NGS・PCR・in-situハイブリダイゼーション・マイクロアレイ
出版日: 2020年07月14日
発行: MarketsandMarkets
ページ情報: 英文 293 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の癌・腫瘍プロファイリングの市場は予測期間中10.9%のCAGRで推移し、2020年の83億米ドルから、2025年には139億米ドルの規模に成長すると予測されています。癌の発生率の増加、個別化医療の需要の拡大、癌のプロファイリングにおけるバイオマーカー利用の増加、癌研究とその資金の増加、技術的発展などの要因が同市場の成長を推進しています。しかし一方で、不十分な法規制と償還シナリオが市場のさらなる成長の障壁となっています。地域別で見ると、アジア太平洋地域が予測期間中、最大の市場シェアを占めると予測されています。同地域の成長は、癌の発症率の急増、プロテオミクスおよびゲノミクス研究の拡大、研究資金の拡大、製薬およびバイオテクノロジー企業による投資の拡大、個別化治療法に対する認知度の拡大などの要因が同地域の成長を推進しています。

当レポートでは、世界の癌・腫瘍プロファイリングの市場を調査し、市場の定義と概要、COVID-19およびその他の市場影響因子の分析、市場規模の推移・予測、技術・癌の種類・バイオマーカータイプ・用途・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • 市場力学
    • 成長推進因子
    • 成長阻害因子
    • 市場機会
    • 課題

第6章 産業分析

  • 産業動向
  • COVID-19の影響

第7章 市場分析・予測:技術別

  • COVID-19の影響
  • 免疫学的検査
  • 次世代シーケンシング
  • PCR
  • IN SITUハイブリダイゼーション
  • マイクロアレイ
  • 質量分析
  • その他

第8章 市場分析・予測:癌の種類別

  • 乳癌
  • 肺癌
  • 結腸直腸癌
  • 前立腺癌
  • メラノーマ
  • その他

第9章 市場分析・予測:バイオマーカータイプ別

  • 遺伝的バイオマーカー
  • タンパク質バイオマーカー
  • その他

第10章 市場分析・予測:用途別

  • COVID-19の影響
  • 研究
    • バイオマーカー発見
    • 個別改良
  • 臨床応用
    • 診断
    • 予後
    • モニタリング・治療
    • スクリーニング

第11章 市場分析・予測:地域別

  • COVID-19の影響
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第12章 競合情勢

  • 概要
  • 競合リーダーシップマッピング
  • 競争状況・動向

第13章 企業プロファイル

  • ILLUMINA, INC.
  • QIAGEN N.V.
  • NEOGENOMICS, INC.
  • SYSMEX CORPORATION
  • HTG MOLECULAR DIAGNOSTICS, INC.
  • HELOMICS CORPORATION
  • CARIS LIFE SCIENCES
  • NANOSTRING TECHNOLOGIES, INC.
  • RIBOMED BIOTECHNOLOGIES, INC.
  • GUARDANT HEALTH, INC.
  • FOUNDATION MEDICINE
  • F. HOFFMANN-LA ROCHE LTD
  • GENSCRIPT BIOTECH CORPORATION
  • TEMPUS LABS
  • HISTOGENE X
  • 他の有力企業
    • HOLOGIC, INC.
    • BOREAL GENOMICS INC
    • PERTHERA
    • AGENDIA
    • OMNISEQ

第14章 付録

目次
Product Code: MD 4803

The cancer/tumor profiling market is expected to grow at a CAGR of 10.9% in the forecast period.

The global cancer/tumor profiling market size is projected to reach USD 13.9 billion by 2025 from USD 8.3 billion in 2020, at a CAGR of 10.9 %. Factors such as the increasing incidence of cancer, increasing demand for personalized medicine, increasing use of biomarkers in cancer profiling, increasing cancer research and funding, and technological advancements in the field are expected to drive the growth of the cancer/tumor profiling market. However, poor regulatory and reimburement scenario serves as a major challenge for the industry.

By technology, the next generation sequencing segment holds the highest market share during the forecast period.

Based on technology, the cancer/tumor profiling market is segmented into immunoassays, in situ hybridization, next generation sequencing (NGS), polymerase chain reaction (PCR), mass spectrometry, microarrays, and others. The immunoassays segment held the highest market share in 2019. The high market share of this segment can be attributed to the wide adoption of these assays as it is the gold standard to measure the presence and concentration of analytes in a sample.

Based on cancer type, the lung cancer segment is expected to register the highest CAGR during the forecast period.

Based on cancer type, the cancer/tumor profiling market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and others. The lung cancer segment is projected to register the highest CAGR during the forecast period. The significant growth in the lung cancer is attributed to the high incidence rate of lung cancer and the increasing need for early diagnosis.

By biomarker type, the genetic biomarker segment holds the highest market share during the forecast period.

Based on biomarker type, the cancer/tumor profiling market is segmented genetic biomarkers, protein biomarkers, and other biomarkers. The genetic segment held the highest market share in 2019. The high market share of this segment can be attributed to the high adoption of these biomarkers during cancer diagnosis and prognosis and in the biomarker discovery process.

By application type, the research application segment holds the highest market share during the forecast period.

Based on cancer type, the cancer/tumor profiling market is segmented research and clinical applications. The research application segment held the highest market share in 2019. The high market share of this segment can be attributed to the increasing focus on biomarker discovery for drug development along with the rapidly growing field of personalized medicine. Additionally, the increased funding for cancer research is propelling the growth of the market.

By Region, The Asia Pacific region holds the highest market share during the forecast period.

The Asia Pacific holds the highest market share during the forecast period (2020 to 2025).

Rapidly incidence of cancer, growing proteomics and genomics research, increasing research funding, rising investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics in several APAC countries, are supporting the growth of the cancer/tumor market in the Asia Pacific region.

Break of primary participants was as mentioned below:

  • By Company Type - Tier 1-35%, Tier 2-45% and Tier 3-20%
  • By Designation - C-level-35%, D-level-25%, Others-40%
  • By Region - North America-45%, Europe-30%, Asia Pacific-20%, Latin America- 3%, Middle East and Africa-2%

Key players in the cancer/tumor profiling market

The key players operating in the cancer/tumor profiling market include Illumina, Inc. (US), QIAGEN N.V. (Germany), NeoGenomics Laboratories, Inc. (US), HTG Molecular Diagnostics, Inc. (US), Genomic Health Inc. (US), Caris Life Sciences (US), Helomics Corporation (US), NanoString Technologies, Inc. (US), Sysmex Corporation (Japan), Ribomed Biotechnologies, Inc. (US), Guardant Health, Inc. (US), Foundation Medicine (US) Roche Holdings Inc. (Switzerland), (US), GenScript Biotech Corporation (China), Tempus Labs (US), Boreal Genomics Inc (Canada), Perthera (US), Agendia (US), Omniseq (US), Histogene X (Belgium).

Research Coverage:

The report analyzes the cancer/tumor profiling market and aims at estimating the market size and future growth potential of this market based on various segments such as product, distribution channel, and region. The report also includes a product portfolio matrix of various cancer profiling products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:

  • Market Penetration: Comprehensive information on product portfolios offered by the top players in the global cancer/tumor profiling market. The report analyzes this market by product and distribution channel.
  • Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global cancer/tumor profiling market
  • Market Development: Comprehensive information on the lucrative emerging markets by product and distribution channel
  • Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global cancer/tumor profiling market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global cancer/tumor profiling market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION & SCOPE
    • 1.2.1 MARKETS COVERED
    • FIGURE 1 CANCER/TUMOR PROFILING MARKET
    • 1.2.2 YEARS CONSIDERED FOR THE STUDY
  • 1.3 CURRENCY
  • 1.4 STAKEHOLDERS
  • 1.5 LIMITATIONS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY RESEARCH
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY RESEARCH
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Breakdown of primaries
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
      • 2.1.2.3 Key industry insights
  • 2.2 MARKET SIZING & VALIDATION APPROACH
    • FIGURE 4 SEGMENTAL SHARE ANALYSIS ILLUSTRATION
    • FIGURE 5 TOP-DOWN APPROACH
  • 2.3 DATA TRIANGULATION APPROACH
    • FIGURE 6 DATA TRIANGULATION METHODOLOGY
  • 2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

    • FIGURE 7 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020 VS. 2025 (USD MILLION)
    • FIGURE 8 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020 VS. 2025 (USD MILLION)
    • FIGURE 9 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020 VS. 2025 (USD MILLION)
    • FIGURE 10 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2020 VS. 2025 (USD MILLION)
    • FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE CANCER/TUMOR PROFILING MARKET

4 PREMIUM INSIGHTS

  • 4.1 CANCER/TUMOR PROFILING: MARKET OVERVIEW
    • FIGURE 12 INCREASING DEMAND FOR PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH
  • 4.2 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 13 CHINA TO REGISTER THE FASTEST GROWTH IN THE CANCER/ TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
  • 4.3 REGIONAL MIX: CANCER/TUMOR PROFILING MARKET (2020-2025)
    • FIGURE 14 APAC TO WITNESS THE FASTEST GROWTH DURING THE FORECAST PERIOD (2020-2025)
  • 4.4 CANCER/TUMOR PROFILING MARKET: DEVELOPED VS. DEVELOPING MARKETS (2020 VS. 2025)
    • FIGURE 15 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE BETWEEN 2020 & 2025

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 16 CANCER/TUMOR PROFILING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 MARKET DRIVERS
      • 5.2.1.1 Increasing incidence of cancer
    • FIGURE 17 GLOBAL CANCER INCIDENCE, 2008-2030
      • 5.2.1.2 Increasing use of biomarkers in cancer profiling
      • 5.2.1.3 Increasing cancer research and funding
      • 5.2.1.4 Technological advancements
    • TABLE 1 MARKET DRIVERS: IMPACT ANALYSIS
    • 5.2.2 MARKET RESTRAINTS
      • 5.2.2.1 High capital investment
      • 5.2.2.2 Technical issues with sample collection and storage
    • TABLE 2 MARKET RESTRAINTS: IMPACT ANALYSIS
    • 5.2.3 MARKET OPPORTUNITIES
      • 5.2.3.1 Increasing demand for personalized medicine
    • FIGURE 18 LAUNCH OF PERSONALIZED MEDICINE PRODUCTS, 2008-2016
      • 5.2.3.2 Growing need for point-of-care diagnostics
    • TABLE 3 MARKET OPPORTUNITIES: IMPACT ANALYSIS
    • 5.2.4 MARKET CHALLENGES
      • 5.2.4.1 Low biomarker discovery-to-approval ratio
      • 5.2.4.2 Poor regulatory and reimbursement scenario
    • TABLE 4 MARKET CHALLENGES: IMPACT ANALYSIS

6 INDUSTRY INSIGHTS

  • 6.1 INTRODUCTION
  • 6.2 INDUSTRY TRENDS
    • FIGURE 19 INCREASING USE OF INTEGRATED OMICS DATA AND GROWING FOCUS ON LIQUID BIOPSY TESTS ARE KEY MARKET TRENDS
    • 6.2.1 INTEGRATION OF OMICS DATA
    • 6.2.2 ADVANCES IN LIQUID BIOPSY
    • 6.2.3 ORGANOIDS FOR PERSONALIZED MEDICINE
  • 6.3 COVID-19 IMPACT ON THE CANCER/TUMOR PROFILING MARKET
    • FIGURE 20 IMPACT OF COVID-19 ON THE CANCER/TUMOR PROFILING MARKET

7 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
  • 7.2 COVID-19 IMPACT, BY TECHNOLOGY
    • FIGURE 21 IMMUNOASSAYS TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
    • TABLE 5 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 6 CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
  • 7.3 IMMUNOASSAYS
    • 7.3.1 IMMUNOASSAY TESTS IDENTIFY AND ASSESS THE PROGRESSION OF DISEASE, THEREBY PROVIDING INFORMATION VITAL FOR BETTER THERAPEUTIC CHOICES
    • TABLE 7 CANCER/TUMOR PROFILING MARKET FOR IMMUNOASSAYS, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
    • TABLE 8 CANCER/TUMOR PROFILING MARKET FOR IMMUNOASSAYS, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
  • 7.4 NEXT GENERATION SEQUENCING
    • 7.4.1 ADVANCES IN NGS MULTIPLEXING CAPABILITIES ENABLE ONE ASSAY TO PROVIDE A COMPLETE TUMOR MOLECULAR PROFILE
    • TABLE 9 CANCER/TUMOR PROFILING MARKET FOR NEXT GENERATION SEQUENCING, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
    • TABLE 10 CANCER/TUMOR PROFILING MARKET FOR NEXT GENERATION SEQUENCING, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
  • 7.5 POLYMERASE CHAIN REACTION
    • 7.5.1 REAL-TIME PCR HELPS IN THE QUANTIFICATION OF LOW-COPY TRANSCRIPTS, AIDING BIOMARKER IDENTIFICATION
    • TABLE 11 CANCER/TUMOR PROFILING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
    • TABLE 12 CANCER/TUMOR PROFILING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
  • 7.6 IN SITU HYBRIDIZATION
    • 7.6.1 FISH IS THE GOLD STANDARD FOR EVALUATING SOME KEY BIOMARKERS AND PLAYS A CRITICAL ROLE IN GUIDING TARGETED THERAPIES
    • TABLE 13 CANCER/TUMOR PROFILING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
    • TABLE 14 CANCER/TUMOR PROFILING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
  • 7.7 MICROARRAYS
    • 7.7.1 MICROARRAYS ARE WIDELY ADOPTED IN DIAGNOSTICS AS THEY AID IN PREDICTING THE RECURRENCE OF CANCER AFTER TREATMENT
    • TABLE 15 CANCER/TUMOR PROFILING MARKET FOR MICROARRAYS, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
    • TABLE 16 CANCER/TUMOR PROFILING MARKET FOR MICROARRAYS, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
  • 7.8 MASS SPECTROMETRY
    • 7.8.1 TECHNOLOGICAL ADVANCEMENTS ARE SUPPORTING THE ADOPTION OF THIS TECHNOLOGY FOR SENSITIVE, RELIABLE, AND RAPID DIAGNOSIS
    • TABLE 17 CANCER/TUMOR PROFILING MARKET FOR MASS SPECTROMETRY, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
    • TABLE 18 CANCER/TUMOR PROFILING MARKET FOR MASS SPECTROMETRY, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
  • 7.9 OTHER TECHNOLOGIES
    • TABLE 19 CANCER/TUMOR PROFILING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
    • TABLE 20 CANCER/TUMOR PROFILING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY/REGION, 2020-2025 (USD MILLION)

8 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE

  • 8.1 INTRODUCTION
    • FIGURE 22 BREAST CANCER SEGMENT TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
    • TABLE 21 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
    • TABLE 22 CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
  • 8.2 BREAST CANCER
    • 8.2.1 BREAST CANCER IS THE MOST COMMON CANCER FOUND AMONG WOMEN
    • TABLE 23 CANCER/TUMOR PROFILING MARKET FOR BREAST CANCER, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
    • TABLE 24 CANCER/TUMOR PROFILING MARKET FOR BREAST CANCER, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
  • 8.3 LUNG CANCER
    • 8.3.1 MOLECULAR CHARACTERIZATION OF TUMORS USING NGS IS A KEY TOOL FOR THE CLINICAL MANAGEMENT OF NSCLC PATIENTS
    • FIGURE 23 GLOBAL LUNG CANCER INCIDENCE, 2012-2030
    • TABLE 25 CANCER/TUMOR PROFILING MARKET FOR LUNG CANCER, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
    • TABLE 26 CANCER/TUMOR PROFILING MARKET FOR LUNG CANCER, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
  • 8.4 COLORECTAL CANCER
    • 8.4.1 IHC, PCR, MICROARRAYS, AND IMAGING TECHNOLOGIES ARE MAJOR TECHNOLOGIES USED IN COLORECTAL DIAGNOSTICS
    • FIGURE 24 COLORECTAL CANCER INCIDENCE RATE, KEY COUNTRIES (2018)
    • TABLE 27 CANCER/TUMOR PROFILING MARKET FOR COLORECTAL CANCER, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
    • TABLE 28 CANCER/TUMOR PROFILING MARKET FOR COLORECTAL CANCER, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
  • 8.5 PROSTATE CANCER
    • 8.5.1 PROSTATE-SPECIFIC ANTIGEN IS A WIDELY USED FDA-APPROVED BIOMARKER FOR PROSTATE CANCER SCREENING
    • TABLE 29 CANCER/TUMOR PROFILING MARKET FOR PROSTATE CANCER, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
    • TABLE 30 CANCER/TUMOR PROFILING MARKET FOR PROSTATE CANCER, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
  • 8.6 MELANOMA
    • 8.6.1 RT-QPCR IS GENERALLY UTILIZED TO CONDUCT MOLECULAR PROFILING AND ANALYZE BIOMARKERS IN MELANOMAS
    • TABLE 31 CANCER/TUMOR PROFILING MARKET FOR MELANOMA, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
    • TABLE 32 CANCER/TUMOR PROFILING MARKET FOR MELANOMA, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
  • 8.7 OTHER CANCERS
    • TABLE 33 CANCER/TUMOR PROFILING MARKET FOR OTHER CANCERS, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
    • TABLE 34 CANCER/TUMOR PROFILING MARKET FOR OTHER CANCERS, BY COUNTRY/REGION, 2020-2025 (USD MILLION)

9 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE

  • 9.1 INTRODUCTION
    • FIGURE 25 GENETIC BIOMARKERS TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
    • TABLE 35 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
    • TABLE 36 CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
  • 9.2 GENETIC BIOMARKERS
    • 9.2.1 GENETIC BIOMARKERS ARE FREQUENTLY USED IN CLINICAL PRACTICE FOR DIAGNOSIS AND PROGNOSIS
    • TABLE 37 CANCER/TUMOR PROFILING MARKET FOR GENETIC BIOMARKERS, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
    • TABLE 38 CANCER/TUMOR PROFILING MARKET FOR GENETIC BIOMARKERS, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
  • 9.3 PROTEIN BIOMARKERS
    • 9.3.1 PROTEOMIC METHODS SHOWCASE SIGNIFICANT PROMISE FOR THE DISCOVERY OF NOVEL BIOMARKERS
    • TABLE 39 CANCER/TUMOR PROFILING MARKET FOR PROTEIN BIOMARKERS, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
    • TABLE 40 CANCER/TUMOR PROFILING MARKET FOR PROTEIN BIOMARKERS, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
  • 9.4 OTHER BIOMARKERS
    • TABLE 41 CANCER/TUMOR PROFILING MARKET FOR OTHER BIOMARKERS, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
    • TABLE 42 CANCER/TUMOR PROFILING MARKET FOR OTHER BIOMARKERS, BY COUNTRY/REGION, 2020-2025 (USD MILLION)

10 CANCER/TUMOR PROFILING MARKET, BY APPLICATION

  • 10.1 INTRODUCTION
  • 10.2 COVID-19 IMPACT, BY APPLICATION
    • FIGURE 26 RESEARCH APPLICATIONS TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
    • TABLE 43 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2017-2019 (USD MILLION)
    • TABLE 44 CANCER/TUMOR PROFILING MARKET, BY APPLICATION, 2020-2025 (USD MILLION)
  • 10.3 RESEARCH APPLICATIONS
    • TABLE 45 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 46 CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • 10.3.1 BIOMARKER DISCOVERY
      • 10.3.1.1 Biomarkers are being exploited for the development of personalized or precision medicine
    • TABLE 47 CANCER/TUMOR PROFILING MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
    • TABLE 48 CANCER/TUMOR PROFILING MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
    • 10.3.2 PERSONALIZED MEDICINE
      • 10.3.2.1 The field of personalized medicine is witnessing rapid growth in the area of oncology
    • TABLE 49 CANCER/TUMOR PROFILING MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
    • TABLE 50 CANCER/TUMOR PROFILING MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
  • 10.4 CLINICAL APPLICATIONS
    • TABLE 51 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 52 CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • 10.4.1 DIAGNOSTICS
      • 10.4.1.1 Tumor profiling is rapidly gaining momentum in the area of diagnostics
    • TABLE 53 CANCER/TUMOR PROFILING MARKET FOR DIAGNOSTICS, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
    • TABLE 54 CANCER/TUMOR PROFILING MARKET FOR DIAGNOSTICS, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
    • 10.4.2 PROGNOSTICS
      • 10.4.2.1 Advancements in molecular biology are aiding the uptake of tumor profiling in this segment
    • TABLE 55 CANCER/TUMOR PROFILING MARKET FOR PROGNOSTICS, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
    • TABLE 56 CANCER/TUMOR PROFILING MARKET FOR PROGNOSTICS, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
    • 10.4.3 MONITORING & TREATMENT
      • 10.4.3.1 Multiplatform profiling analyses are gaining recognition for monitoring and treatment among cancer patients
    • TABLE 57 CANCER/TUMOR PROFILING MARKET FOR MONITORING & TREATMENT, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
    • TABLE 58 CANCER/TUMOR PROFILING MARKET FOR MONITORING & TREATMENT, BY COUNTRY/REGION, 2020-2025 (USD MILLION)
    • 10.4.4 SCREENING
      • 10.4.4.1 Screening tests help in deciding if diagnostic tests are required by the patient
    • TABLE 59 CANCER/TUMOR PROFILING MARKET FOR SCREENING, BY COUNTRY/REGION, 2017-2019 (USD MILLION)
    • TABLE 60 CANCER/TUMOR PROFILING MARKET FOR SCREENING, BY COUNTRY/REGION, 2020-2025 (USD MILLION)

11 CANCER/TUMOR PROFILING MARKET, BY REGION

  • 11.1 INTRODUCTION
  • 11.2 COVID-19 IMPACT, BY REGION
    • FIGURE 27 CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC SNAPSHOT
    • TABLE 61 CANCER/TUMOR PROFILING MARKET, BY REGION, 2017-2019 (USD MILLION)
    • TABLE 62 CANCER/TUMOR PROFILING MARKET, BY REGION, 2020-2025 (USD MILLION)
  • 11.3 NORTH AMERICA
    • FIGURE 28 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET SNAPSHOT
    • TABLE 63 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 64 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2020-2025 (USD MILLION)
    • TABLE 65 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 66 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 67 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
    • TABLE 68 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
    • TABLE 69 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
    • TABLE 70 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
    • TABLE 71 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 72 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 73 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 74 NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • 11.3.1 US
      • 11.3.1.1 US dominates the North American cancer/tumor profiling market
    • TABLE 75 US: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 76 US: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 77 US: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
    • TABLE 78 US: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
    • TABLE 79 US: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
    • TABLE 80 US: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
    • TABLE 81 US: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 82 US: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 83 US: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 84 US: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • 11.3.2 CANADA
      • 11.3.2.1 Growing public-private partnerships to promote proteomics research are expected to drive the market in Canada
    • TABLE 85 CANADA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 86 CANADA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 87 CANADA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
    • TABLE 88 CANADA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
    • TABLE 89 CANADA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
    • TABLE 90 CANADA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
    • TABLE 91 CANADA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 92 CANADA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 93 CANADA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 94 CANADA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
  • 11.4 EUROPE
    • FIGURE 29 EUROPE: CANCER/TUMOR PROFILING MARKET SNAPSHOT
    • TABLE 95 EUROPE: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 96 EUROPE: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2020-2025 (USD MILLION)
    • TABLE 97 EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 98 EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 99 EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
    • TABLE 100 EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
    • TABLE 101 EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
    • TABLE 102 EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
    • TABLE 103 EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 104 EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 105 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 106 EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION) 158
    • 11.4.1 GERMANY
      • 11.4.1.1 Advancements in proteomics and genomics research are expected to drive market growth
    • TABLE 107 GERMANY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 108 GERMANY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 109 GERMANY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
    • TABLE 110 GERMANY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
    • TABLE 111 GERMANY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
    • TABLE 112 GERMANY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
    • TABLE 113 GERMANY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 114 GERMANY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 115 GERMANY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 116 GERMANY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • 11.4.2 UK
      • 11.4.2.1 Growth in the life sciences industry and the increase in academia-industry partnerships will be the key factors driving the market
    • TABLE 117 UK: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 118 UK: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 119 UK: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
    • TABLE 120 UK: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
    • TABLE 121 UK: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
    • TABLE 122 UK: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
    • TABLE 123 UK: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 124 UK: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 125 UK: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 126 UK: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • 11.4.3 FRANCE
      • 11.4.3.1 Growth in this market is primarily driven by increasing investments in life science R&D for infrastructural development
    • TABLE 127 FRANCE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 128 FRANCE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 129 FRANCE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
    • TABLE 130 FRANCE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
    • TABLE 131 FRANCE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
    • TABLE 132 FRANCE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
    • TABLE 133 FRANCE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 134 FRANCE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 135 FRANCE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 136 FRANCE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • 11.4.4 ITALY
      • 11.4.4.1 Increasing investment in cancer and translational research is expected to propel market growth during the forecast period
    • TABLE 137 ITALY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 138 ITALY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 139 ITALY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
    • TABLE 140 ITALY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
    • TABLE 141 ITALY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
    • TABLE 142 ITALY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
    • TABLE 143 ITALY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 144 ITALY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 145 ITALY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 146 ITALY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • 11.4.5 SPAIN
      • 11.4.5.1 Rising incidence of cancer and increasing focus on cancer biomarkers by various medical societies to support market growth in Spain
    • TABLE 147 SPAIN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 148 SPAIN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 149 SPAIN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
    • TABLE 150 SPAIN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
    • TABLE 151 SPAIN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
    • TABLE 152 SPAIN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
    • TABLE 153 SPAIN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 154 SPAIN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 155 SPAIN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 156 SPAIN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • 11.4.6 REST OF EUROPE
    • TABLE 157 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 158 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 159 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
    • TABLE 160 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
    • TABLE 161 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
    • TABLE 162 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
    • TABLE 163 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 164 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 165 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 166 REST OF EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
  • 11.5 ASIA PACIFIC
    • FIGURE 30 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET SNAPSHOT
    • TABLE 167 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2017-2019 (USD MILLION)
    • TABLE 168 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY COUNTRY, 2020-2025 (USD MILLION)
    • TABLE 169 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 170 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 171 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
    • TABLE 172 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
    • TABLE 173 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
    • TABLE 174 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
    • TABLE 175 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 176 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 177 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 178 ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • 11.5.1 JAPAN
      • 11.5.1.1 Large number of research initiatives towards the development of precision medicine supporting market growth in Japan
    • TABLE 179 JAPAN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 180 JAPAN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 181 JAPAN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
    • TABLE 182 JAPAN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
    • TABLE 183 JAPAN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
    • TABLE 184 JAPAN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
    • TABLE 185 JAPAN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 186 JAPAN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 187 JAPAN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 188 JAPAN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • 11.5.2 CHINA
      • 11.5.2.1 China has the fastest-growing research sector in the APAC region
    • TABLE 189 CHINA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 190 CHINA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 191 CHINA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
    • TABLE 192 CHINA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
    • TABLE 193 CHINA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
    • TABLE 194 CHINA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
    • TABLE 195 CHINA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 196 CHINA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 197 CHINA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 198 CHINA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • 11.5.3 INDIA
      • 11.5.3.1 Increasing pharma R&D and government funding in the biotechnology industry are the major factors driving market growth in India
    • TABLE 199 INDIA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 200 INDIA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 201 INDIA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
    • TABLE 202 INDIA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
    • TABLE 203 INDIA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
    • TABLE 204 INDIA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
    • TABLE 205 INDIA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 206 INDIA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 207 INDIA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 208 INDIA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • 11.5.4 REST OF ASIA PACIFIC
    • TABLE 209 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 210 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 211 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
    • TABLE 212 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
    • TABLE 213 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
    • TABLE 214 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
    • TABLE 215 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 216 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 217 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 218 REST OF ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
  • 11.6 LATIN AMERICA
    • 11.6.1 GROWING PROTEOMICS RESEARCH IN THE FIELD OF CANCER ALONG WITH THE RISING USE OF ADVANCED TECHNIQUES TO DRIVE MARKET GROWTH
    • TABLE 219 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 220 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 221 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
    • TABLE 222 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
    • TABLE 223 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
    • TABLE 224 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
    • TABLE 225 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 226 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 227 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 228 LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
  • 11.7 MIDDLE EAST & AFRICA
    • 11.7.1 GROWING GENOMICS AND PROTEOMICS RESEARCH AND INCREASING RESEARCH COLLABORATIONS ARE EXPECTED TO SUPPORT MARKET GROWTH
    • TABLE 229 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017-2019 (USD MILLION)
    • TABLE 230 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2020-2025 (USD MILLION)
    • TABLE 231 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017-2019 (USD MILLION)
    • TABLE 232 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2020-2025 (USD MILLION)
    • TABLE 233 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017-2019 (USD MILLION)
    • TABLE 234 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2020-2025 (USD MILLION)
    • TABLE 235 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 236 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)
    • TABLE 237 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017-2019 (USD MILLION)
    • TABLE 238 MIDDLE EAST: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020-2025 (USD MILLION)

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
    • FIGURE 31 COLLABORATIONS, PARTNERSHIPS, AND AGREEMENTS-KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS FROM 2016 TO APRIL 2020
  • 12.2 COMPETITIVE LEADERSHIP MAPPING
    • 12.2.1 VISIONARY LEADERS
    • 12.2.2 INNOVATORS
    • 12.2.3 DYNAMIC DIFFERENTIATORS
    • 12.2.4 EMERGING COMPANIES
    • FIGURE 32 CANCER/TUMOR PROFILING MARKET: COMPETITIVE LEADERSHIP MAPPING (2018)
  • 12.3 COMPETITIVE SITUATION AND TRENDS
    • 12.3.1 PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS
    • TABLE 239 PRODUCT LAUNCHES, 2016-2020
    • 12.3.2 EXPANSIONS
    • TABLE 240 EXPANSIONS, 2016-2020
    • 12.3.3 ACQUISITIONS
    • TABLE 241 ACQUISITIONS, 2016-2020
    • 12.3.4 OTHER STRATEGIES
    • TABLE 242 OTHER STRATEGIES, 2016-2020

13 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)**

  • 13.1 ILLUMINA, INC.
    • FIGURE 33 ILLUMINA, INC.: COMPANY SNAPSHOT (2019)
  • 13.2 QIAGEN N.V.
    • FIGURE 34 QIAGEN N.V.: COMPANY SNAPSHOT (2019)
  • 13.3 NEOGENOMICS, INC.
    • FIGURE 35 NEOGENOMICS, INC.: COMPANY SNAPSHOT (2019)
  • 13.4 SYSMEX CORPORATION
    • FIGURE 36 SYSMEX CORPORATION: COMPANY SNAPSHOT (2019)
  • 13.5 HTG MOLECULAR DIAGNOSTICS, INC.
    • FIGURE 37 HTG MOLECULAR DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2019)
  • 13.6 HELOMICS CORPORATION
  • 13.7 CARIS LIFE SCIENCES
  • 13.8 NANOSTRING TECHNOLOGIES, INC.
    • FIGURE 38 NANOSTRING TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2019)
  • 13.9 RIBOMED BIOTECHNOLOGIES, INC.
  • 13.10 GUARDANT HEALTH, INC.
    • FIGURE 39 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2019)
  • 13.11 FOUNDATION MEDICINE
  • 13.12 F. HOFFMANN-LA ROCHE LTD
    • FIGURE 40 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2019)
  • 13.13 GENSCRIPT BIOTECH CORPORATION
    • FIGURE 41 GENSCRIPT: COMPANY SNAPSHOT (2019)
  • 13.14 TEMPUS LABS
  • 13.15 HISTOGENE X
  • 13.16 OTHER COMPANIES
    • 13.16.1 HOLOGIC, INC.
    • 13.16.2 BOREAL GENOMICS INC
    • 13.16.3 PERTHERA
    • 13.16.4 AGENDIA
    • 13.16.5 OMNISEQ

*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

14 APPENDIX

  • 14.1 INSIGHTS OF INDUSTRY EXPERTS
  • 14.2 DISCUSSION GUIDE
  • 14.3 DKNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.4 AVAILABLE CUSTOMIZATIONS
  • 14.5 RELATED REPORTS
  • 14.6 AUTHOR DETAILS 302
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.